Receive the latest updates from Matrix Medical in real time to understand product information.
Hangzhou Matrix Medical Technology Co., Ltd. learned today that its independently developed coronary artery papillary balloon dilation catheter has officially obtained registration approval from the National Medical Products Administration (NMPA) and has successfully obtained a Class III medical device registration certificate with registration number 20253030002. This is the second Class III interventional device registration certificate obtained by Matrix Medical, marking another important breakthrough for the company in the field of medical device research and development.
Product Name | Coronary Papillary Dilatation Balloon Catheter |
Registration Certificate Number | NMPA20253030002 |
Registration Category | Class III |
Scope of Application | This product is suitable for balloon dilation of coronary artery stenosis |
In the future, Matrix Medical will continue to focus on the cutting-edge needs of clinical vascular disease treatment, further enrich product types, optimize product performance, and contribute to the localization and innovation of medical devices.
About Matrix
Future oriented innovation intervention technology platform
Hangzhou Matrix Medical Technology Co., Ltd. (hereinafter referred to as' Juzheng Medical ') was founded in 2021 and is the first high-tech enterprise in China to master intravascular photochemical cross-linking technology. It focuses on the research and development and production of innovative medical devices in the field of vascular intervention, and is committed to the research and development of a series of natural vascular stent products without implantation. Juzheng Medical is headquartered in Hangzhou Future Science and Technology City and has a production base of 1700 square meters in Anji.
In the future, Matrix Medical will continue to adhere to the concept of "intervention without implantation", develop new interventional medical devices, take solving clinical pain points as the first starting point, truly provide new solutions for patients undergoing vascular intervention therapy, and actively promote the research and development of innovative technologies to further promote the development of the field of vascular intervention therapy.
